Major Depressive Disorder Clinical Trial
The study will investigate functional and metabolic changes in the course of antidepressive
treatments.
The investigators will apply different imaging methods to investigate the effects of
antidepressive interventions on resting state neural activity, functional activation during
cognitive and emotional stimulation, neurotransmitter concentrations as well as
concentrations of brain- derived neurotrophic factor.
The study will investigate functional and metabolic changes in the course of antidepressive
treatments.
The investigators will apply different imaging methods to investigate the effects of
antidepressive interventions on resting state neural activity, functional activiation during
cognitive and emotional stimulation, neurotransmitter concentrations as well as
concentrations of brain- derived neurotrophic factor.
The investigators hypothesize that antidepressive interventions modulate the excitatory
glutamatergic system and thereby increase either the concentration of glutamate or the
glutamate/ glutamine ratio. These metabolic changes are accompanied by altered functional
activation in medial and lateral prefrontal areas during emotional and cognitive stimulation,
respectively. After longterm treatment, excitatory glutamate and inhibitory
gamma-aminobutyric acid concentrations adapt to a new homeostatic level which is reflected in
antidepressive response or remission of symptoms. The investigators assume that the levels of
glutamate and gamma-aminobutyric acid determine the amplitude of BOLD responses during
emotional and cognitive stimulation. Furthermore, the investigators hypothesize that the
plasma concentration of brain- derived neurotrophic factor might be a predictor for therapy
response and changes in the course of treatment.
With our protocol we adhere to the rules of good scientific practice and observe all relevant
laws, regulations and guidelines that pertain to the project. The investigators' study is in
compliance with the Declaration of Helsinki and approved by the local ethics committee.
Storage of data is in accordance with german privacy laws.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
| Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
| Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
| Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
| Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
| Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
| Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
| Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
| Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
| Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
| Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
| Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
| Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
| Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
| Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
| Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
| Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
| Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
| Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
| Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |